Skip to main content
SpringerLink
Log in

Management of Acute Coronary Syndromes

  • Chapter
Cardiac Markers

Part of the book series: Pathology and Laboratory Medicine ((PLM))

  • 187 Accesses

Abstract

The term “acute coronary syndrome” (ACS) describes the spontaneous presentation of acute ischemic heart disease, and encompasses the diagnoses of unstable angina, non-ST elevation myocardial infarction (MI) (NSTEMI), and ST elevation MI (STEMI). Because Q waves can be detected only retrospectively, previous classification schemes based the presence or absence of Q waves are less useful than schemes that classify patients based on the presence or absence of ST-segment elevation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Yamagishi M, Terashima M, Awano K, et al. Morphology of vulnerable coronary plaque: insights from follow-up of patients examined by intravascular ultrasound before an acute coronary syndrome. J Am Coll Cardiol 2000; 35: 106–111.

    Article  PubMed  CAS  Google Scholar 

  2. Sinapius D. Zur morphologie verschliessender koronarthromben. Dtsch Med Wochenschr 1972; 97: 544.

    Article  PubMed  CAS  Google Scholar 

  3. Gerhardt W, Katus H, Ravkilde J, et al. (1991) S-troponin T in suspected ischemic myocardial injury compared with mass and catalytic concentrations of S-creatine kinase isoenzyme MB. Clin Chem 1991; 37: 1405–1411.

    Google Scholar 

  4. Hamm CW, Ravkilde J, Gerhardt W, et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992; 327: 146–150.

    Article  PubMed  CAS  Google Scholar 

  5. Joint ESC/ACC Committee. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959–969.

    Article  Google Scholar 

  6. Wagner GS, Bahit MC, Criger D, et al. Moving toward a new definition of acute myocardial infarction for the 21st century: status of the ESC/ACC consensus conference. European Society of Cardiology and American College of Cardiology. J Electrocardiol 2000; 33: 57–59.

    Article  PubMed  Google Scholar 

  7. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000; 36: 970–1062.

    Article  PubMed  CAS  Google Scholar 

  8. Aroney CN, Boyden AN, Jelinek MV, Thompson P, Tonkin AM, White H. Management of unstable angina. Guidelines-2000. Med J Aust 2000; 173 (Suppl): S65–S88.

    Google Scholar 

  9. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90: 775–778.

    Article  PubMed  CAS  Google Scholar 

  10. Fyfe AI, Rothenberg LS, DeBeer FC, Cantor RM, Rotter JI, Lusis AJ. Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes. Circulation 1997; 96: 2914–2919.

    Article  PubMed  CAS  Google Scholar 

  11. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417–424.

    Article  PubMed  CAS  Google Scholar 

  12. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 462–466.

    Article  PubMed  CAS  Google Scholar 

  13. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998; 31: 1460–1465.

    Article  PubMed  CAS  Google Scholar 

  14. Rebuzzi AG, Quaranta G, Liuzzo G, et al. Incremental prognostic value of serum concentrations of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol 1998; 82: 715–719.

    Article  PubMed  CAS  Google Scholar 

  15. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein concentrations in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997; 96: 4204–4210.

    Article  Google Scholar 

  16. de Winter RJ, Bholasingh R, Lijmer JG, et al. Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction. Cardiovasc Res 1999; 42: 240–245.

    Article  PubMed  Google Scholar 

  17. Biasucci LM, Liuzzo G, Grillo RL, et al. Increased concentrations of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99: 855–860.

    Article  PubMed  CAS  Google Scholar 

  18. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing concentrations of interleukin (IL)1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999; 99: 2079–2084.

    Article  PubMed  CAS  Google Scholar 

  19. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 343: 1139–1143.

    Google Scholar 

  20. Blatt DL, Chew DP, Simoons ML, et al. An increased white cell count is an independent predictor of mortality in patients with acute coronary syndromes. Circulation 2000; 102 (Suppl II): 776.

    Google Scholar 

  21. Cannon CP, McCabe CH, Wilcox RG, Bentley JH, Braunwald E. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators. Am J Cardiol 2001; 87: 636–639.

    Article  Google Scholar 

  22. Thiemann DR, Coresh J, Schulman SP, Gerstenblith G, Oetgen WJ, Powe NR. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation. 2000; 101: 2239–2246.

    Article  PubMed  CAS  Google Scholar 

  23. Brass LM, Lichtman JH, Wang Y, Gurwitz JH, Radford MJ, Krumholz HM. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. Stroke 2000; 31: 1802–1811.

    Article  PubMed  CAS  Google Scholar 

  24. Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA 2001; 285: 190–192.

    Article  PubMed  CAS  Google Scholar 

  25. TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 89: 1545–1556.

    Google Scholar 

  26. The RISC Group. (1990) Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–830.

    Article  Google Scholar 

  27. Cannon CP, Moliterno DJ, Every N, et al. Implementation of AHCPR guidelines for unstable angina in 1996. Unfortunate differences between men and women. Results from the GUARANTEE registry. J Am Coll Cardiol 1997; 29 (Suppl): 217A.

    Google Scholar 

  28. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of anti-platelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308: 81.

    Google Scholar 

  29. The Persantine-Aspirin Reinfarction Study Research Group. Persantine and aspirin in coronary heart disease. Circulation 1994; 62: 449–461.

    Google Scholar 

  30. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell’Angina Instabile Group. Circulation 82: 17–26.

    Google Scholar 

  31. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 348: 1329–1339.

    Google Scholar 

  32. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502.

    Article  PubMed  CAS  Google Scholar 

  33. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996; 276: 811–815.

    Article  PubMed  CAS  Google Scholar 

  34. Becker RC, Cannon CP, Tracy RP, et al. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardial infarction. Am Heart J 1996; 131: 421–433.

    Article  PubMed  CAS  Google Scholar 

  35. Chong BH. Heparin induced thrombocytopenia. Br J Haematol 89: 431–439.

    Google Scholar 

  36. Massonnet-Castel S, Pelissier E, Bara L, et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis 1986; 16: 139–146.

    PubMed  CAS  Google Scholar 

  37. Van Ryn-McKenna J, Cai L, Ofosu FA, Hirsh J, Buchanan MR. Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thromb Haemost 63: 271–274.

    Google Scholar 

  38. FRISC Investigators. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease. Lancet 1996; 347: 561–568.

    Google Scholar 

  39. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol 1997; 29: 43–48.

    Article  PubMed  CAS  Google Scholar 

  40. Morrow DA, Antman EM, Tanasijevic M, et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol 36: 1812–1817.

    Google Scholar 

  41. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRISC). Circulation 1997; 96: 61–68.

    Article  PubMed  CAS  Google Scholar 

  42. FRAXIS Investigators. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAXIS (FRAxiparine in Ischemic Syndrome). Eur Heart J 1999; 20: 1553–1562.

    Article  Google Scholar 

  43. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447–452.

    Article  PubMed  CAS  Google Scholar 

  44. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation 1999; 100: 1593–1601.

    Article  PubMed  CAS  Google Scholar 

  45. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 100: 1602–1608.

    Google Scholar 

  46. Goodman S, Langer A, Demers C, et al. One year follow-up of the ESSENCE trial: sustained clinical benefit. Can J Cardiol 1998; 14: 122F.

    Google Scholar 

  47. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events (unstable angina or non-Q-Wave myocardial infarction). Circulation 1998; 97: 1702–1707.

    Article  PubMed  CAS  Google Scholar 

  48. O’Brien BJ, Willan A, Blackhouse G, Goeree R, Cohen M, Goodman S. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? Am Heart J 2000; 139: 423–429.

    Article  PubMed  Google Scholar 

  49. Hirsh J. Low-molecular-weight heparin: a review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Circulation 1998; 98: 1575–1582.

    Article  PubMed  CAS  Google Scholar 

  50. Antman EA, Handin R. Low-molecular-weight heparins. An intriguing new twist with profound implications. Circulation 1998; 98: 287–289.

    Article  PubMed  CAS  Google Scholar 

  51. Montelescot G, Phillippe F, Ankri A, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease. Beneficial effects of enoxaparin. Circulation 1998; 98: 294–299.

    Article  Google Scholar 

  52. FRISC II Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 701–707.

    Google Scholar 

  53. OASIS-2 Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2). Lancet 1999; 353: 429–438.

    Article  Google Scholar 

  54. Thrombin Inhibition in Myocardial Ischaemia (TRIM) study group. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Eur Heart J 1997; 18: 1416–1625.

    Google Scholar 

  55. GUSTO IIb investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries. N Engl J Med 1996; 335: 775–782.

    Article  Google Scholar 

  56. Rao AK, Sun L, Chesebro JH, et al. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma concentrations of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial. Circulation 1996; 94: 2389–2395.

    Article  PubMed  CAS  Google Scholar 

  57. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999; 282: 2058–2067.

    Article  PubMed  CAS  Google Scholar 

  58. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 1994; 89: 81–88.

    Article  PubMed  CAS  Google Scholar 

  59. Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 2002; 105: 557–563.

    Article  PubMed  CAS  Google Scholar 

  60. Anand SS, Yusuf S, Pogue J, Weitz JI, Flather M. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. Circulation 98: 1064–1070.

    Google Scholar 

  61. Huynh T, Theroux P, Bogaty P, Nasmith J, Solymoss S. Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation 2001; 103: 3069–3074.

    Article  PubMed  CAS  Google Scholar 

  62. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms. N Engl J Med 1998; 338: 1488–1497.

    Article  Google Scholar 

  63. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998; 339: 436–443.

    Google Scholar 

  64. PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM). N Engl J Med 1998; 338: 1498–1505.

    Article  Google Scholar 

  65. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001; 357: 1915–1924.

    Article  PubMed  CAS  Google Scholar 

  66. Cohen M, Theroux P, Weber S, et al. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999; 71: 273–281.

    Article  PubMed  CAS  Google Scholar 

  67. Neumann FJ, Zohlnhofer D, Fakhoury L, Ott I, Gawaz M, Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 1999; 34: 1420–1426.

    Article  PubMed  CAS  Google Scholar 

  68. Le Breton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 1996; 28: 1643–1651.

    Article  PubMed  Google Scholar 

  69. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335–371.

    Article  PubMed  CAS  Google Scholar 

  70. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489–497.

    Article  PubMed  CAS  Google Scholar 

  71. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–153.

    Article  PubMed  CAS  Google Scholar 

  72. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.

    Google Scholar 

  73. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol concentrations. N Engl J Med 1998; 339: 1349–1357.

    Article  Google Scholar 

  74. Sacks RNI, Pfeffer MA, Moye LA, et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol concentrations. N Engl J Med 1996; 335: 1001–1009.

    Article  PubMed  CAS  Google Scholar 

  75. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001; 87: 819–822.

    Article  PubMed  CAS  Google Scholar 

  76. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711–1718.

    Article  PubMed  CAS  Google Scholar 

  77. FRISC II Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 708–715.

    Google Scholar 

  78. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879–1887.

    Article  PubMed  CAS  Google Scholar 

  79. Boden WE, O’Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Qwave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998; 338: 1785–1792.

    Article  PubMed  CAS  Google Scholar 

  80. Zhao XQ, Theroux P, Snapinn SM, Sax FL. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction: angiographic results from the PRISM-PLUS trial (Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms). Circulation 1999; 100: 1609–1615.

    Article  PubMed  CAS  Google Scholar 

  81. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344: 1895–1903.

    Google Scholar 

  82. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T concentrations. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999; 340: 1623–1629.

    Article  PubMed  CAS  Google Scholar 

  83. O’Shea JC, Hafley GE, Greenberg S, et al. Platelet glycoprotein Ilb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA 2001; 285: 2468–2473.

    Article  PubMed  Google Scholar 

  84. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/ IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888–1894.

    Article  PubMed  CAS  Google Scholar 

  85. Moussa I, Oetgen M, Roubin G, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999; 99: 2364–2366.

    Article  PubMed  CAS  Google Scholar 

  86. Berger PB, Bell MR, Hasdai D, Grill DE, Melby S, Holmes DR, Jr. Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. Circulation 1999; 99: 248–253.

    Article  PubMed  CAS  Google Scholar 

  87. The EPIC Investigation. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956–261.

    Google Scholar 

  88. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplastycontrolled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/ IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352: 87–92.

    Article  Google Scholar 

  89. Calvin JE, Klein LW, VandenBerg BJ, et al. Risk stratification in unstable angina. Prospective validation of the Braunwald classification. JAMA 1995; 273: 136–141.

    Article  PubMed  CAS  Google Scholar 

  90. Calvin JE, Klein LW, VandenBerg EJ, Meyer P, Parrillo JE. Validated risk stratification model accurately predicts low risk in patients with unstable angina. J Am Coll Cardiol 2000; 36: 1803–1808.

    Article  PubMed  CAS  Google Scholar 

  91. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000; 284: 835–842.

    Article  PubMed  CAS  Google Scholar 

  92. Sabatine MS, Januzzi JL, Snapinn S, Theroux P, Jang I. A risk score system for predicting adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris. Am J Cardiol 88: 488–492.

    Google Scholar 

Download references

Authors
  1. Constantine N. Aroney
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James A. de Lemos
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, CT, USA

    Alan H. B. Wu PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Aroney, C.N., de Lemos, J.A. (2003). Management of Acute Coronary Syndromes. In: Wu, A.H.B. (eds) Cardiac Markers. Pathology and Laboratory Medicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-385-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-385-9_2

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-319-0

  • Online ISBN: 978-1-59259-385-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation